Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattl…
$76.39
$1.17 (-1.51%)
Last close via Marketstack
Margins and capital returns are both well above average: 39.35% operating margin, ROIC at 25.11%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue growth slowed to 2.3%, essentially flat. This is a business that needs a catalyst.
Even for strong businesses, today's 13x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
12.5x earnings, 14.4x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$9.53B
▲ +2.3% YoY
Net Income (TTM)
$2.67B
▲ +7.5% YoY
Op. Margin
39.18%
▲ +1.2pp YoY
ROIC
24.72%
▲ +0.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$2.24B
▼ -0.7% YoY
Op. Cash Flow (TTM)
$2.79B
▼ -1.7% YoY
Net Debt
$7.30B
Cash & Equiv.
$1.94B
5Y CAGR: +7.2%
5Y CAGR: +6.4%
Continue Research